Ida Sonni1, Ryogo Minamimoto1, Lucia Baratto1, Sanjiv S Gambhir2, Andreas M Loening2,3, Shreyas S Vasanawala3,4, Andrei Iagaru5. 1. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, H2200, Stanford, CA, 94305, USA. 2. Molecular Imaging Program at Stanford, Department of Radiology, Stanford University, Stanford, CA, USA. 3. Division of Body MRI, Department of Radiology, Stanford University, Stanford, CA, USA. 4. Radiological Science Laboratory, Department of Radiology, Stanford University, Stanford, CA, USA. 5. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, H2200, Stanford, CA, 94305, USA. aiagaru@stanford.edu.
Abstract
PURPOSE: The purpose of this study is to prospectively evaluate the performance of sodium 18F]fluoride (Na[18F]F)/2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) simultaneous time-of-flight enabled positron emission tomography (PET)/magnetic resonance imaging (MRI) for the detection of skeletal metastases in selected patients with advanced breast and prostate cancers. PROCEDURE: The institutional review board approved this HIPAA-compliant protocol. Written informed consent was obtained from each patient. A total of 74 patients (23 women and 51 men with breast and prostate cancer, respectively) referred for standard-of-care whole-body bone scintigraphy (WBBS) were enrolled in this prospective study. All patients underwent a [99mTc]methyldiphosphonate ([99mTc]MDP) WBBS followed by Na[18F]F/[18F]FDG PET/MRI. Lesions detected by each imaging modality were tabulated and a lesion-based and patient-based analysis was conducted. RESULTS: On a patient-based analysis, [99mTc]MDP WBBS identified skeletal lesions in 37 patients and PET/MRI in 45 patients. On a lesion-based analysis, WBBS identified a total of 81 skeletal lesions, whereas PET/MRI identified 140 lesions. Additionally, PET/MRI showed extra-skeletal lesions in 19 patients, including lymph nodes (16), prostate (4) lung (3), and liver (2) lesions. CONCLUSIONS: The ability of Na[18F]F/[18F]FDG PET/MRI to identify more skeletal lesions than 99mTc-MDP WBBS and to additionally identify extra-skeletal disease may be beneficial for patient care and represent an alternative to the single modalities performed separately. Na[18F]F/[18F]FDG PET/MRI is a promising approach for evaluation of skeletal and extra-skeletal lesions in a selected population of breast and prostate cancer patients.
PURPOSE: The purpose of this study is to prospectively evaluate the performance of sodium 18F]fluoride (Na[18F]F)/2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) simultaneous time-of-flight enabled positron emission tomography (PET)/magnetic resonance imaging (MRI) for the detection of skeletal metastases in selected patients with advanced breast and prostate cancers. PROCEDURE: The institutional review board approved this HIPAA-compliant protocol. Written informed consent was obtained from each patient. A total of 74 patients (23 women and 51 men with breast and prostate cancer, respectively) referred for standard-of-care whole-body bone scintigraphy (WBBS) were enrolled in this prospective study. All patients underwent a [99mTc]methyldiphosphonate ([99mTc]MDP) WBBS followed by Na[18F]F/[18F]FDG PET/MRI. Lesions detected by each imaging modality were tabulated and a lesion-based and patient-based analysis was conducted. RESULTS: On a patient-based analysis, [99mTc]MDP WBBS identified skeletal lesions in 37 patients and PET/MRI in 45 patients. On a lesion-based analysis, WBBS identified a total of 81 skeletal lesions, whereas PET/MRI identified 140 lesions. Additionally, PET/MRI showed extra-skeletal lesions in 19 patients, including lymph nodes (16), prostate (4) lung (3), and liver (2) lesions. CONCLUSIONS: The ability of Na[18F]F/[18F]FDG PET/MRI to identify more skeletal lesions than 99mTc-MDP WBBS and to additionally identify extra-skeletal disease may be beneficial for patient care and represent an alternative to the single modalities performed separately. Na[18F]F/[18F]FDG PET/MRI is a promising approach for evaluation of skeletal and extra-skeletal lesions in a selected population of breast and prostate cancerpatients.
Entities:
Keywords:
Breast and prostate cancer; Magnetic resonance imaging; Na[18F]F/[18F]FDG PET/MRI
Authors: William J Gradishar; Benjamin O Anderson; Ron Balassanian; Sarah L Blair; Harold J Burstein; Amy Cyr; Anthony D Elias; William B Farrar; Andres Forero; Sharon Hermes Giordano; Matthew Goetz; Lori J Goldstein; Clifford A Hudis; Steven J Isakoff; P Kelly Marcom; Ingrid A Mayer; Beryl McCormick; Meena Moran; Sameer A Patel; Lori J Pierce; Elizabeth C Reed; Kilian E Salerno; Lee S Schwartzberg; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; George Somlo; Melinda Telli; John H Ward; Dorothy A Shead; Rashmi Kumar Journal: J Natl Compr Canc Netw Date: 2015-04 Impact factor: 11.908
Authors: Frank I Lin; Jyotsna E Rao; Erik S Mittra; Kavitha Nallapareddy; Alka Chengapa; David W Dick; Sanjiv Sam Gambhir; Andrei Iagaru Journal: Eur J Nucl Med Mol Imaging Date: 2011-11-08 Impact factor: 9.236
Authors: Srinath C Sampath; Srihari C Sampath; Camila Mosci; Amelie M Lutz; Juergen K Willmann; Erik S Mittra; Sanjiv S Gambhir; Andrei Iagaru Journal: Clin Nucl Med Date: 2015-03 Impact factor: 7.794
Authors: H Schirrmeister; A Guhlmann; K Elsner; J Kotzerke; G Glatting; M Rentschler; B Neumaier; H Träger; K Nüssle; S N Reske Journal: J Nucl Med Date: 1999-10 Impact factor: 10.057
Authors: Andrei Iagaru; Erik Mittra; Camila Mosci; David W Dick; Mike Sathekge; Vineet Prakash; Victor Iyer; Paula Lapa; Jorge Isidoro; Joao M de Lima; Sanjiv Sam Gambhir Journal: J Nucl Med Date: 2012-12-14 Impact factor: 10.057
Authors: Andrei Iagaru; Erik Mittra; Shahriar S Yaghoubi; David W Dick; Andrew Quon; Michael L Goris; Sanjiv Sam Gambhir Journal: J Nucl Med Date: 2009-03-16 Impact factor: 10.057
Authors: J Orcajo-Rincon; J Muñoz-Langa; J M Sepúlveda-Sánchez; G C Fernández-Pérez; M Martínez; E Noriega-Álvarez; S Sanz-Viedma; J C Vilanova; A Luna Journal: Clin Transl Oncol Date: 2022-02-13 Impact factor: 3.340
Authors: Nils Martin Bruckmann; Julian Kirchner; Lale Umutlu; Wolfgang Peter Fendler; Robert Seifert; Ken Herrmann; Ann-Kathrin Bittner; Oliver Hoffmann; Svjetlana Mohrmann; Christina Antke; Lars Schimmöller; Marc Ingenwerth; Katharina Breuckmann; Andreas Stang; Christian Buchbender; Gerald Antoch; Lino M Sawicki Journal: Eur Radiol Date: 2021-04-28 Impact factor: 5.315